- Home
- PRFX vs ENVB Comparison
PRFX vs ENVB Comparison
Compare PRFX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- ENVB
- Stock Information
- Founded
- PRFX 2007
- ENVB 1994
- Country
- PRFX Israel
- ENVB United States
- Employees
- PRFX N/A
- ENVB N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- ENVB Health Care
- Exchange
- PRFX Nasdaq
- ENVB Nasdaq
- Market Cap
- PRFX 3.0M
- ENVB 3.3M
- IPO Year
- PRFX 2020
- ENVB N/A
- Fundamental
- Price
- PRFX $3.16
- ENVB $1.36
- Analyst Decision
- PRFX Hold
- ENVB
- Analyst Count
- PRFX 1
- ENVB 0
- Target Price
- PRFX N/A
- ENVB N/A
- AVG Volume (30 Days)
- PRFX 3.2M
- ENVB 564.4K
- Earning Date
- PRFX 01-01-0001
- ENVB 03-25-2025
- Dividend Yield
- PRFX N/A
- ENVB N/A
- EPS Growth
- PRFX N/A
- ENVB N/A
- EPS
- PRFX N/A
- ENVB N/A
- Revenue
- PRFX N/A
- ENVB N/A
- Revenue This Year
- PRFX N/A
- ENVB N/A
- Revenue Next Year
- PRFX N/A
- ENVB N/A
- P/E Ratio
- PRFX N/A
- ENVB N/A
- Revenue Growth
- PRFX N/A
- ENVB N/A
- 52 Week Low
- PRFX $0.43
- ENVB $1.26
- 52 Week High
- PRFX $16.63
- ENVB $657.00
- Technical
- Relative Strength Index (RSI)
- PRFX 49.34
- ENVB 16.91
- Support Level
- PRFX $3.22
- ENVB $1.26
- Resistance Level
- PRFX $5.47
- ENVB $1.70
- Average True Range (ATR)
- PRFX 0.34
- ENVB 0.17
- MACD
- PRFX 0.04
- ENVB 2.34
- Stochastic Oscillator
- PRFX 15.97
- ENVB 12.20
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.